Alex

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors

BEIJING & BARCELONA, Spain--(BUSINESS WIRE)--#ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech…

Tikehau Capital and Nikko Asset Management Enter Into Advanced Discussion to Form a Strategic Partnership in Asia

  PARIS--(BUSINESS WIRE)--Regulatory News: Tikehau Capital (Paris:TKO), the global alternative asset management group, and Nikko…

Mitsui Chemicals Develops Diffrarâ„¢ Optical Polymer Wafers for AR Glasses

The Lineup includes the world’s first 8-inch polymer wafer for AR glasses TOKYO--(BUSINESS WIRE)--Mitsui Chemicals,…

BELFOR Expands Service Portfolio in Thailand with TBCC

BANGKOK--(BUSINESS WIRE)--#BELFOR--BELFOR Thailand, the local arm of the global leader in damage restoration services, is…

InnoCare Appoints Xin Fu as Chief Financial Officer

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and…

Lydia AI Expands Reach in Korea Through Strategic Partnerships with Hecto Data and Tobecon

SEOUL, South Korea--(BUSINESS WIRE)--#canada--Lydia AI, a leading Canadian health AI company, is thrilled to announce…

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment…

Maximizing Operational Efficiency: Strategies for Manufacturing Success

Operational efficiency is defined as the ability of an organization to use its resources effectively…

FARFETCH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Farfetch Limited and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds…

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found…